These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 391622)

  • 1. An experimentally controlled evaluation of the effect of inositol nicotinate upon the digital blood flow in patients with Raynaud's phenomenon.
    Holti G
    J Int Med Res; 1979; 7(6):473-83. PubMed ID: 391622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative thermal imaging to assess inositol nicotinate treatment for Raynaud's syndrome.
    Ring EF; Porto LO; Bacon PA
    J Int Med Res; 1981; 9(6):393-400. PubMed ID: 7319129
    [No Abstract]   [Full Text] [Related]  

  • 3. Quantitative thermographic assessment of inositol nicotinate therapy in Raynaud's phenomena.
    Ring EF; Bacon PA
    J Int Med Res; 1977; 5(4):217-22. PubMed ID: 881094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease.
    Sunderland GT; Belch JJ; Sturrock RD; Forbes CD; McKay AJ
    Clin Rheumatol; 1988 Mar; 7(1):46-9. PubMed ID: 3044673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hexopal in Raynaud's disease.
    Aylward M
    J Int Med Res; 1979; 7(6):484-91. PubMed ID: 520652
    [No Abstract]   [Full Text] [Related]  

  • 6. A plethysmographic study of the effect of tetranicotinoylfructose (Bradilan) on digital blood flow in primary and secondary Raynaud's phenomenon.
    Antcliff AC; Bouhoutsos J; Martin P; Morris T
    Angiology; 1974 May; 25(5):312-6. PubMed ID: 4823806
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacotherapy of Raynaud's phenomenon.
    Belch JJ; Ho M
    Drugs; 1996 Nov; 52(5):682-95. PubMed ID: 9118818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of peripheral arterial insufficiency with inositoli nicotinas (Hexanicit).
    Hentzer E
    Scand J Clin Lab Invest Suppl; 1967; 99():226-32. PubMed ID: 4862834
    [No Abstract]   [Full Text] [Related]  

  • 9. [Study of the plethysmographic amplification factor during vasodilator treatment. Healthy subject versus primary Raynaud phenomenon].
    Lasfargues G; Royere D; Perrotin D; Titon JP; Soutif D; Guilmot JL
    J Mal Vasc; 1987; 12(4):319-22. PubMed ID: 3694055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute effects of nifedipine on digital blood flow in human subjects with Raynaud's phenomenon: a double blind placebo controlled trial.
    Wise RA; Malamet R; Wigley FM
    J Rheumatol; 1987 Apr; 14(2):278-83. PubMed ID: 3298649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute effect of topical minoxidil on digital blood flow in patients with Raynaud's phenomenon.
    Whitmore SE; Wigley FM; Wise RA
    J Rheumatol; 1995 Jan; 22(1):50-4. PubMed ID: 7699682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology of capillary circulation: Raynaud's disease.
    Arnot RS; Boroda C; Peacock JH
    Angiology; 1978 Jan; 29(1):48-52. PubMed ID: 343651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Experience with the medical treatment of chronic cerebrovascular insufficiency: bamethan and inositol nicotinate versus placebo].
    Cucinotta D; Silvestrini C; Mancini M; Maini C; Passeri M
    G Clin Med; 1981 May; 62(5):339-50. PubMed ID: 6115790
    [No Abstract]   [Full Text] [Related]  

  • 16. Acute effects of misoprostol on digital circulation in patients with Raynaud's phenomenon.
    Wise RA; Wigley F
    J Rheumatol; 1994 Jan; 21(1):80-3. PubMed ID: 8151594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostaglandin E1 in severe Raynaud's phenomenon.
    Pardy BJ; Hoare MC; Eastcott HH; Miles CC; Needham TN; Harbourne T; Ellis BW
    Surgery; 1982 Dec; 92(6):953-65. PubMed ID: 6890719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of digital artery adrenoceptors in Raynaud's disease.
    Cooke JP; Creager SJ; Scales KM; Ren C; Tsapatsaris NP; Beetham WP; Creager MA
    Vasc Med; 1997; 2(1):1-7. PubMed ID: 9546943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of the Raynaud's phenomenon with piracetam.
    Moriau M; Lavenne-Pardonge E; Crasborn L; von Frenckell R; Col-Debeys C
    Arzneimittelforschung; 1993 May; 43(5):526-35. PubMed ID: 8328997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antihypertensive combination-therapy with inositol nicotinate in essential hypertension].
    Krämer KD; Ghabussi P; Hochrein H
    Med Welt; 1977 Jul; 28(27):1198-1201. PubMed ID: 329049
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.